Puma Biotechnology, Inc.

Release Summary

The FDA has posted Oncologic Drugs Advisory Committee (ODAC) briefing documents on its website in advance of the May 24 meeting scheduled to review Puma Biotechnology's drug, PB272 (neratinib).

Puma Biotechnology, Inc.